600080 Stock Overview
Researches, develops, produces, and sells pharmaceuticals in China. More details
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Ginwa Enterprise (Group) Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥6.68 |
52 Week High | CN¥8.06 |
52 Week Low | CN¥4.53 |
Beta | 0.25 |
11 Month Change | 4.05% |
3 Month Change | 15.37% |
1 Year Change | -16.81% |
33 Year Change | -8.62% |
5 Year Change | 14.78% |
Change since IPO | -12.35% |
Recent News & Updates
Shareholder Returns
600080 | CN Pharmaceuticals | CN Market | |
---|---|---|---|
7D | -0.1% | -1.5% | -2.1% |
1Y | -16.8% | -9.4% | 2.8% |
Return vs Industry: 600080 underperformed the CN Pharmaceuticals industry which returned -4.8% over the past year.
Return vs Market: 600080 underperformed the CN Market which returned 5.4% over the past year.
Price Volatility
600080 volatility | |
---|---|
600080 Average Weekly Movement | 5.0% |
Pharmaceuticals Industry Average Movement | 7.3% |
Market Average Movement | 8.3% |
10% most volatile stocks in CN Market | 12.6% |
10% least volatile stocks in CN Market | 5.6% |
Stable Share Price: 600080 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 600080's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1996 | 553 | n/a | www.ginwa.com.cn |
Ginwa Enterprise (Group) Inc. researches, develops, produces, and sells pharmaceuticals in China. The company offers orthopedic, immune, pediatric, antibiotic, digestive system, gynecological, cardiovascular, antipyretic, analgesic, antiviral, and other products. It offers its products in the form of tablets, capsules, granules, powders, mixtures, oral solutions, syrups, and external solutions.
Ginwa Enterprise (Group) Inc. Fundamentals Summary
600080 fundamental statistics | |
---|---|
Market cap | CN¥2.36b |
Earnings (TTM) | -CN¥15.51m |
Revenue (TTM) | CN¥581.53m |
4.1x
P/S Ratio-151.9x
P/E RatioIs 600080 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
600080 income statement (TTM) | |
---|---|
Revenue | CN¥581.53m |
Cost of Revenue | CN¥133.11m |
Gross Profit | CN¥448.42m |
Other Expenses | CN¥463.93m |
Earnings | -CN¥15.51m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.044 |
Gross Margin | 77.11% |
Net Profit Margin | -2.67% |
Debt/Equity Ratio | 2.8% |
How did 600080 perform over the long term?
See historical performance and comparison